# MicroRNAs utilization as effective factors on hematopoietic stem cell transplantation, its outcomes and prognosis; a comprehensive systematic review

## TL;DR

This paper reviews how microRNAs affect outcomes of hematopoietic stem cell transplantation, offering insights into improving treatment success and patient prognosis.

## Contribution

The study systematically identifies 47 microRNAs influencing HSCT outcomes, highlighting their roles in survival, relapse, and engraftment.

## Key findings

- 47 microRNAs were found to influence hematopoietic stem cell transplantation outcomes.
- Specific microRNAs act as tumor suppressors or oncogenes in leukemia patients undergoing HSCT.
- MicroRNA expression correlates with relapse in multiple myeloma and engraftment recovery after HSCT.

## Abstract

The therapeutic method for many malignant and non-malignant diseases is hematopoietic stem cell transplantation (HSCT), but it is not always fully successful in all patients. Indeed, HSCT can be influenced by a variety of factors. Here we reviewed the effect of microRNAs (miRs) on HSCT-related outcomes, like survival, infections, relapse, engraftment, and so on, systematically.

WOS, Scopus, PubMed, Google Scholar, and ProQuest databases were searched. The PRISMA guideline was performed, and 24 studies were included through quality assessment. Classified data extraction was done based on the type of disease.

The systematic review identified 47 miRs effective on HSCT. The role of miRs as tumor suppressors or oncogenes is reported in acute myeloblastic and lymphoblastic leukemia patients undergoing HSCT due to their effects on overall or event-free survival. Additionally, relapse after HSCT in multiple myeloma is correlated with miRs expression. Also, recovery from post-autologous HSCT cytopenia or platelet and neutrophil engraftment can be influenced by miRs. We highlighted here reports on specific miRs.

We reported prognostic miRs for in-depth clinical management of the HSCT process and its outcomes. Also, miRs are introduced for the prevention of HSCT-related complications, and future studies are suggested to evaluate personalized medicine’s utilization of miRs in therapeutic methods like HSCT in neoplasia.